is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Nominations for Awards will follow the three tracks of this year’s CPhI North America conference: drug manufacturing, drug development and delivery, and biopharma:
Entries will be judged by a world-class panel of CPhI judges, who will consider both the social responsibility and innovativeness of the projects submitted for consideration. All projects must meet the criteria for eligibility* to be considered by the judges; projects not meeting these criteria will be automatically rejected. Shortlisted projects will be invited to the Awards ceremony to make a short presentation.
The Chemicals Knowledge Awards in partnership with CPhI North America celebrate ethical innovation throughout the Pharmaceutical industry.
A lot of companies in the pharmaceutical industry are showing remarkable social responsibility, all the way from their drug manufacturing, through development and to delivery. At Chemicals Knowledge, they believe that those projects deserve to be recognised, celebrated and shared.
That’s why Chemicals Knowledge is partnering with CPhI North America for the launch of the Ethical Innovation Awards - to bring together the best of the best in the pharmaceutical industry.Judges in our first-ever Ethical Innovation Awards are looking for the best and brightest – and most socially responsible – in pharmaceutical innovation.Every year, the World Health Organization (WHO) identifies the top 10 threats to global health. In 2019, this included environmental and social issues such as climate change and vaccine hesitancy, as well as anti-microbial resistance, dengue, Ebola and other high-threat pathogens, HIV and noncommunicable diseases (e.g. diabetes, cancer, heart disease). While some of these are clearly receiving a huge amount of attention in terms of pharma industry R&D, there is a worrying lack of investment in other areas, the most obvious of those being anti-microbial resistance, which is seeing more than one pharma giant cease R&D in this area due to it being a ‘difficult’ field with limited financial return.At the same time, our world is struggling with unprecedented environmental challenges. Last year, the Intergovernmental Panel on Climate Change (IPCC) reported that to keep the rise in global temperatures below 1.5C this century, emissions of carbon dioxide would have to be cut by 45% by 2030. This led to the catchphrase that we had “12 years to save the planet,” and there is no doubt that many organizations – both public and private – are rising to the challenge.